Prelude Therapeutics Incorporated (PRLD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 7 | 12 | 22 | 39 |
| Operating profit | $m | -105 | -67 | ||||||
| Net profit | $m | -57 | -112 | -115 | -122 | -127 | -99 | -60 | -56 |
| EPS reported | $ | -1.29 | -0.79 | ||||||
| Operating cashflow per share | $ | -0.73 | -0.34 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.73 | -0.34 | ||||||
| Free cash flow | $m | -56 | -33 | ||||||
| Net debt | $m | -103 | -152 | ||||||
| Book value equity | $m | 69 | 134 | ||||||
| Book value per share | $ | 0.89 | 1.36 | ||||||
| Number of shares | m | 76.96 | 98.39 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.36 | 1.21 | ||||||
| P/S LTM | x | 13.33 | 7.22 | ||||||
| P/FCF LTM | x | -2.87 | -4.87 | ||||||
| EV/EBITDA LTM | x | -1.48 | -2.45 | ||||||
| EV/Sales LTM | x | 11.89 | 13.70 | ||||||
| Earnings Yield LTM | % | -44.58% | -11.08% | ||||||
| FCF Yield | % | -34.83% | -20.55% | ||||||
| Quality | |||||||||
| ROE | % | -144.96% | -75.35% | ||||||
| ROIC | % | -1.15% | -43.74% | ||||||
| Operating margin | % | -8.61% | -3.01% | ||||||
| Gross margin | % | +85.91% | +98.26% | ||||||
| FCF/Sales | % | -464.32% | -148.30% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +73.43% | +220.34% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -3.17 | -1.88 | ||||||
| Net Debt/EBITDA | x | 0.18 | 0.15 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +7.70% | ||||||
| Net debt/Equity | x | -1.50 | -1.13 | ||||||
| Gross debt/equity | x | 0.26 | 0.13 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Prelude Therapeutics Incorporated (PRLD)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free